Ebribafusp Biosimilar – Anti-C3 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2225; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Ebribafusp Biosimilar, also known as Anti-C3 fusion protein, is a therapeutic protein that has been designed to target the complement system, specifically the C3 protein. This biosimilar is a research grade compound that has shown promising results in pre-clinical studies and is currently undergoing clinical trials for various medical conditions. In this article, we will discuss the structure, activity, and potential applications of Ebribafusp Biosimilar.
Ebribafusp Biosimilar is a fusion protein that consists of two components: a humanized antibody fragment and a C3 inhibitor. The antibody fragment is derived from a human monoclonal antibody and has been modified to specifically target the C3 protein. The C3 inhibitor is a small molecule that binds to the C3 protein and prevents its activation. The fusion of these two components results in a potent therapeutic protein that can effectively inhibit the complement system.
The structure of Ebribafusp Biosimilar is similar to that of the natural C3 protein, allowing it to bind to the same receptors and exert its inhibitory effects. This makes it an ideal therapeutic agent for targeting the complement system without causing any adverse immune reactions.
Ebribafusp Biosimilar works by inhibiting the activity of the C3 protein, which is a key component of the complement system. The complement system is a part of the immune system that helps in fighting off infections and clearing damaged cells. However, in certain medical conditions, the complement system can become overactive and cause damage to healthy cells and tissues. This is where Ebribafusp Biosimilar comes in.
By targeting the C3 protein, Ebribafusp Biosimilar prevents it from being activated and triggering the complement cascade. This helps in reducing inflammation, tissue damage, and other harmful effects caused by an overactive complement system. Additionally, Ebribafusp Biosimilar has also been shown to have immunomodulatory effects, which further enhances its therapeutic potential.
Ebribafusp Biosimilar has shown promising results in pre-clinical studies and is currently being evaluated in clinical trials for various medical conditions. Some of the potential applications of this therapeutic protein include:
Ebribafusp Biosimilar, also known as Anti-C3 fusion protein, is a promising therapeutic protein that has shown potential in targeting the complement system. Its unique structure, potent activity, and potential applications make it a valuable addition to the field of therapeutic proteins. With ongoing clinical trials, we can expect to see more promising results and potential uses for this biosimilar in the near future.
ProteoGenix catalogue number PX-TA2225. For research use only.
Target: Ebribafusp Biosimilar – Anti-C3 fusion protein – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
